Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira Technologies OXY announced that its INSPIRA™ ART100 Cardiopulmonary Bypass System has received 510(k) class II clearance from the FDA.
The FDA clearance is a significant milestone for the company, suggesting technological and innovative advancements.
CEO Dagi Ben Noon and Chairman Professor Benad Goldwasser expressed their appreciation for investors and partners and highlighted the strategic importance of this clearance.
Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) has announced the start of production of the INSPIRA ART100 medical device. The device is being contract manufactured by a leading technology company and the first batch will be used in initial sites pending FDA approval.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.